Relative expression as a percentage of the neat mRNA expression is plotted versus relative integrity as a percentage of the neat mRNA integrity, determined by relative area using both CE and RP-IP HPLC. c Loss in mRNA purity to adduct formation in 2 vaccine formulations is plotted over 3 ...
Vaccine-induced T-cell responses were evaluated using T-cell proliferation assays and IFN-γ ELISpot. In the T-cell proliferation assay, T-cells from pre- and post-vaccination blood samples of the patients were incubated with either transfected DCs (tDCs) or non-transfected DCs (nDCs) and the...
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide range of incurable diseases. Recent rapid advances in biotechnology and molecular medicine have enabled the production of almost any functional protein/peptide in the human body by introducing mRNA as a vaccine or ...
mRNA vaccines have been revolutionary in terms of their rapid development and prevention of SARS-CoV-2 infections during the COVID-19 pandemic, and this technology has considerable potential for application to the treatment of cancer. Compared with traditional cancer vaccines based on proteins or pept...
Fig. 4 The commonly used mRNA vaccine delivery systems 3.1 脂质体及脂质复合物 脂质体是由具有亲水头部和疏水尾部的两亲性聚合物分子在水相溶液中形成的一种类似细胞膜的脂质结构,被认为是较为安全可靠的非病毒递送载体之一,也...
However, traditional vaccine approaches such as live attenuated vaccines and inacti- vated viral vaccines that have achieved good preventive effects in a variety of infectious diseases are not suitable for tumor vaccine development [2]. Therefore, the devel- opment of more effective and versatile ...
2. A Synergistic Lipid Nanoparticle Encapsulating mRNA Shingles Vaccine Induces Potent Immune Responses and Protects Guinea Pigs from Viral Challenges 译：封装mRNA 带状疱疹疫苗的协同脂质纳米颗粒可诱导有效的免疫反应并保护豚鼠免受病毒攻击 作者列表:Cheng X;Liu S;Sun J;Liu L;Ma X;Li J;Fan B;Yang C...
Along with the newer platforms, more traditional vaccine approaches are currently being evaluated in clinical trials (WHO, 2020). For instance, SARS-CoV-2 recombinant protein vaccines are being tested in combination with FDA-approved adjuvants such as MF59 (O’Hagan, 2007), an oil-in-water ...
vaccine compared with that of modified vaccines. CureVac has pointed to the changing SARS-CoV-2 variant landscape during the conduct of its trial, which was not the case for BNT162b2 or mRNA-1273; others have noted CureVac’s use of a lower dose (12 µg) versus those of BNT162b2 ...
Investigating two versus three doses of mRNA vaccine in patients with cirrhosisdoi:10.1038/s41575-022-00711-wJordan HindsonNature Reviews Gastroenterology & HepatologyNature Publishing Group UKNature Reviews Gastroenterology & Hepatology